Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 310,153 shares of the biopharmaceutical company's stock after buying an additional 115,528 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 0.28% of Regeneron Pharmaceuticals worth $220,931,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $6,364,000. Morse Asset Management Inc boosted its stake in Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock worth $5,053,000 after purchasing an additional 43 shares in the last quarter. Anchor Investment Management LLC grew its position in Regeneron Pharmaceuticals by 212.0% during the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock worth $902,000 after purchasing an additional 583 shares during the last quarter. Sculati Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock valued at $1,970,000 after purchasing an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its holdings in shares of Regeneron Pharmaceuticals by 19.0% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock worth $5,575,000 after buying an additional 848 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $15.61 on Friday, reaching $605.61. 1,606,415 shares of the company were exchanged, compared to its average volume of 745,022. The company has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44. The business has a 50-day moving average price of $626.49 and a 200 day moving average price of $709.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 1 year low of $525.99 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the firm posted $9.55 earnings per share. The company's quarterly revenue was down 3.7% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analysts Set New Price Targets

REGN has been the topic of several research reports. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Finally, UBS Group reduced their price target on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $892.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.